Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

Patent metadata

Field	Value
Publication number	US-9499791-B2
Application number	US-24537908-A
Country	US
Kind code	B2
Filing date	Oct 3, 2008
Priority date	May 1, 1998
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the use of MDCs for the increase of skeletal muscle.

First claim

We claim:

1. A method of augmenting a skeletal muscle in a mammal suffering from a muscle pathology comprising:
a) isolating muscle-derived progenitor cells (MDCs) by a method comprising:
(i) isolating skeletal muscle from a human;
(ii) storing the skeletal muscle at 4° C. for 5 to 7 days;
(iii) suspending the human skeletal muscle in a medium in a first cell culture container between 30 and 120 minutes thereby producing a cell population of adherent cells and a population of non-adherent cells;
(iv) isolating the medium containing a population of non-adherent cells;
(v) transferring the medium containing the population of the non-adherent cells to a second cell culture container;
(vi) allowing the population of the transferred non-adherent cells from step (v) to attach to the walls of the second cell culture container, wherein the incubation is for 1 to 3 days;
(vii) removing the medium from the second container and replacing with new medium after the 1 to 3 days of incubation; and
(viii) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are MDCs and are desmin+;

b) expanding the isolated MDCs in culture for between 10 and 20 days; and
c) administering a therapeutically effective amount of the expanded MDCs to the skeletal muscle in the mammal suffering from a muscle pathology; allowing the MDCS to engraft to the skeletal muscle and thereby augmenting the skeletal muscle in the mammal.

2. The method of claim 1 , wherein the mammal is a human.

3. The method of claim 1 , wherein the expanded MDCs are administered by injecting the MDCs into the skeletal muscle of the mammal.

4. The method of claim 1 , wherein the skeletal muscle of the mammal has a defect.

5. The method of claim 4 , wherein the expanded MDCs are administered by applying them onto, into or around the site of the defect.

6. The method of claim 5 , wherein the expanded MDCs are applied through injection.

7. A method of augmenting a skeletal muscle in a mammal suffering from a muscle pathology comprising:
a) isolating muscle-derived progenitor cells (MDCs) by a method comprising:
(i) isolating skeletal muscle from a human;
(ii) storing the skeletal muscle at 4° C. for 5 to 7 days;
(iii) suspending the human skeletal muscle in a medium in a first cell culture container between 30 and 120 minutes thereby producing a cell population of adherent cells and a population of non-adherent cells;
(iv) isolating the medium containing a population of non-adherent cells;
(v) transferring the medium containing the population of the non-adherent cells to a second cell culture container;
(vi) allowing the population of the transferred non-adherent cells from step (v) to attach to the walls of the second cell culture container, wherein the incubation is for 1 to 3 days;
(vii) removing the medium from the second container and replacing with new medium after the 1 to 3 days of incubation; and
(viii) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are MDCs and are desmin+;

b) expanding the isolated MDCs in culture for between 10 and 20 days;
c) freezing the isolated MDCs to a temperature between about −25° C. and −90° C.;
d) thawing the frozen isolated MDCs at room temperature with an equal volume of physiologic saline;
and e) administering the thawed MDCs to the skeletal muscle in the mammal suffering from a muscle pathology; allowing the MDCS to engraft to the skeletal muscle and thereby augmenting the skeletal muscle in the mammal.

8. The method of claim 7 , wherein the mammal is a human.

9. The method of claim 7 , wherein the expanded MDCs are administered by injecting the MDCs into the skeletal muscle of the mammal.

10. The method of claim 7 , wherein the skeletal muscle of the mammal has a defect.

11. The method of claim 10 , wherein the expanded MDCs are administered by applying them onto, into or around the site of the defect.

12. The method of claim 11 , wherein the MDCs are applied through injection.

Assignees

• Payne Thomas
• Jankowski Ronald
• Pruchnic Ryan
• Chancellor Michael
• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Payne Thomas
• Jankowski Ronald
• Pruchnic Ryan
• Chancellor Michael

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title